



(51) International Patent Classification:

C07D 231/20 (2006.01) **A61K 31/415** (2006.01)
C07D 231/22 (2006.01) **A61P 9/00** (2006.01)
C07D 401/04 (2006.01) **A61P 11/00** (2006.01)
C07D 401/12 (2006.01) **A61P 37/00** (2006.01)
C07D 403/12 (2006.01) **A61P 25/28** (2006.01)
C07D 405/12 (2006.01) **A61P 29/00** (2006.01)
C07D 413/12 (2006.01) **A61P 13/12** (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:

PCT/EP2011/051038

(22) International Filing Date:

26 January 2011 (26.01.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10305080.3 26 January 2010 (26.01.2010) EP
 61/309,119 1 March 2010 (01.03.2010) US

(71) **Applicant** (for all designated States except US):
SANOFI [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **RUF, Sven** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **PERNERSTORFER, Josef** [AT/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SADOWSKI, Thorsten** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HORSTICK, Georg** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHREUDER, Herman** [NL/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BUNING, Christian** [DE/DE]; c/o Sanofi-

Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **OLPP, Thomas** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHEIPER, Bodo** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WIRTH, Klaus** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) **Agent:** **LÖWRICK, Oliver**; K 801, c/o Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K 801, 65926 Frankfurt (DE).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS



(57) **Abstract:** The present invention relates to compounds of the formula I, wherein A, D, E, G, R¹⁰, R³⁰, R⁴⁰, R⁵⁰ and R⁶⁰ have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.